BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21112812)

  • 1. Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic.
    Nguyen-Van-Tam JS; Nicholson KG
    J Clin Virol; 2011 Feb; 50(2):183. PubMed ID: 21112812
    [No Abstract]   [Full Text] [Related]  

  • 2. The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu.
    Weber JT; Nicoll A; Bridges CB; Ciancio BC
    BMJ; 2010 Jan; 340():c130. PubMed ID: 20071425
    [No Abstract]   [Full Text] [Related]  

  • 3. Global transmission of oseltamivir-resistant influenza.
    Moscona A
    N Engl J Med; 2009 Mar; 360(10):953-6. PubMed ID: 19258250
    [No Abstract]   [Full Text] [Related]  

  • 4. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.
    Baz M; Abed Y; Papenburg J; Bouhy X; Hamelin ME; Boivin G
    N Engl J Med; 2009 Dec; 361(23):2296-7. PubMed ID: 19907034
    [No Abstract]   [Full Text] [Related]  

  • 5. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
    Lin X; Zhou J; Zhang Y; Wu J; Zhang F; Li Z; Zhang Y; Bi S; Shu Y; Wang Y
    Biochem Biophys Res Commun; 2009 Dec; 390(4):1305-8. PubMed ID: 19879239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oseltamivir resistance: what does it mean clinically?
    Baum SG
    Clin Infect Dis; 2009 Dec; 49(12):1836-7. PubMed ID: 19911972
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness of neuraminidase inhibitors for severe influenza.
    Fry AM
    Lancet Respir Med; 2014 May; 2(5):346-8. PubMed ID: 24815800
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
    Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
    Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitors--the story behind the Cochrane review.
    Doshi P
    BMJ; 2009 Dec; 339():b5164. PubMed ID: 19995813
    [No Abstract]   [Full Text] [Related]  

  • 10. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa.
    Besselaar TG; Naidoo D; Buys A; Gregory V; McAnerney J; Manamela JM; Blumberg L; Schoub BD
    Emerg Infect Dis; 2008 Nov; 14(11):1809-10. PubMed ID: 18976580
    [No Abstract]   [Full Text] [Related]  

  • 11. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Wolkewitz M; Schumacher M
    Lancet Respir Med; 2014 Jul; 2(7):e8-9. PubMed ID: 24948434
    [No Abstract]   [Full Text] [Related]  

  • 12. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Leonardi-Bee J; Venkatesan S; Muthuri SG; Nguyen-Van-Tam JS; Myles PR;
    Lancet Respir Med; 2014 Jul; 2(7):e10-2. PubMed ID: 24948433
    [No Abstract]   [Full Text] [Related]  

  • 13. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Jones M; Del Mar C; Hama R
    Lancet Respir Med; 2014 Jul; 2(7):e9-e10. PubMed ID: 24948431
    [No Abstract]   [Full Text] [Related]  

  • 14. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Antes G; Meerpohl JJ
    Lancet Respir Med; 2014 Jul; 2(7):e10. PubMed ID: 24948429
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus.
    van der Vries E; Stelma FF; Boucher CA
    N Engl J Med; 2010 Sep; 363(14):1381-2. PubMed ID: 20879894
    [No Abstract]   [Full Text] [Related]  

  • 17. Influenza viruses resistant to neuraminidase inhibitors.
    Nitsch-Osuch A; Brydak LB
    Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
    Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
    Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance. A 'wimpy' flu strain mysteriously turns scary.
    Enserink M
    Science; 2009 Feb; 323(5918):1162-3. PubMed ID: 19251605
    [No Abstract]   [Full Text] [Related]  

  • 20. Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study.
    Miller PE; Rambachan A; Hubbard RJ; Li J; Meyer AE; Stephens P; Mounts AW; Rolfes MA; Penn CR
    PLoS One; 2012; 7(9):e43491. PubMed ID: 22984431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.